SCA
Sippican Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-20,753
| Closed | -$662K | – | 110 |
|
|
2024
Q4 | $662K | Sell |
20,753
-9,560
| -32% | -$305K | 0.48% | 67 |
|
|
2024
Q3 | $874K | Buy |
30,313
+7,135
| +31% | +$206K | 0.61% | 57 |
|
|
2024
Q2 | $889K | Buy |
23,178
+7,249
| +46% | +$278K | 0.7% | 51 |
|
|
2024
Q1 | $936K | Sell |
15,929
-75
| -0.5% | -$4.41K | 0.73% | 51 |
|
|
2023
Q4 | $958K | Buy |
16,004
+170
| +1% | +$10.2K | 0.75% | 51 |
|
|
2023
Q3 | $602K | Buy |
15,834
+6,930
| +78% | +$264K | 0.54% | 63 |
|
|
2023
Q2 | $811K | Sell |
8,904
-2,265
| -20% | -$206K | 0.75% | 55 |
|
|
2023
Q1 | $737K | Buy |
+11,169
| New | +$737K | 0.7% | 55 |
|
|
2021
Q4 | – | Sell |
-6,513
| Closed | -$215K | – | 110 |
|
|
2021
Q3 | $215K | Buy |
+6,513
| New | +$215K | 0.19% | 108 |
|